Pham Quang X 4

What Happened
Pham Quang, a 10% owner of Cadrenal Therapeutics, sold a total of 4,126 shares in two open-market transactions under a Rule 10b5-1 plan. On 2026-06-16 he sold 3,613 shares at a weighted average price of $3.18 for $11,489 (F2). On 2026-06-17 he sold 513 shares at a weighted average price of $3.16 for $1,621 (F3). Combined proceeds were about $13,110. These transactions are sales (not purchases).

Key Details

• Transaction dates: 2026-06-16 (3,613 shares, WAP $3.18, total $11,489) and 2026-06-17 (513 shares, WAP $3.16, total $1,621).
• Price ranges: 6/16 sales occurred at prices between $3.04–$3.37 (F2); 6/17 sales between $3.14–$3.20 (F3). Reporting person can provide per-price breakdown on request.
• Plan/authorization: Shares sold pursuant to a Rule 10b5-1 trading plan adopted Sept 25, 2025 (F1).
• Ownership/authority: Pham is trustee of The PVBQ Living Trust and has sole voting and dispositive power over the trust’s shares; the trust’s sole beneficiary is his child (F4).
• Filing timing: Report filed 2026-06-18 covering 6/16–6/17 trades; this appears to be within the typical Section 16 filing window.

Context

• These were routine sales under a pre-established 10b5-1 plan; such plans allow insiders to sell on a schedule and reduce the inference that sales reflect new private information.
• Sales reduce insider holdings but do not, by themselves, indicate company performance or management view. No purchases, option exercises, or awards were reported in this filing.